Study of Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria

NCT03328897 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

418

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Spontaneous Urticaria

Interventions

DRUG: Omalizumab
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals